Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk @entity1 Undergoing Allogeneic Hematopoietic Cell Transplantation for XXXX , Not Identified by the HCT-CI Score.

@entity1 @entity1349 @entity3052
INTRODUCTION: Risk scores have been developed for allogeneic hematopoietic cell transplantation (HCT) outcomes, such as the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) and the modified European Group for Blood and Marrow Transplantation risk score (mEBMT) for @entity3052 . We investigated the influence of these scores for 350 @entity1 who underwent transplantation for @entity3052 ( @entity3052 ). @entity1 AND METHODS: The HCT-CI scores were grouped as 0 to 2 and  >=  3 (231 and 119 @entity1 , respectively) and the mEBMT scores as 0 to 2 and  >=  3 (166 and 184 @entity1 , respectively). RESULTS: Univariate analysis showed a significant association between the HCT-CI score and @entity1349 ( @entity1349 ) (P  = .01), as did the mEBMT score (P  = .002). The 5-year @entity1349 rate was 50% and 34% for a mEBMT score of 0 to 2 and  >=  3, respectively. A subgroup of @entity1 with a mEBMT score of 0 to 1 (n  = 32) demonstrated a favorable @entity1349 of 75% at 5 years. This subgroup was younger (median age, 31 years), in first remission at transplantation, and had related donors. For the HCT-CI, the 5-year @entity1349 was 46% and 34% for a score of 0 to 2 and  >=  3, respectively. @entity1 with an HCT-CI score of 0 (n  = 94) had a 5-year @entity1349 of 44%. Multivariable analysis confirmed both the HCT-CI score and the mEBMT score, as previously grouped, as independent prognostic variables for both @entity1349 (P  = .02 and P  = .001, respectively) and nonrelapse mortality (NRM) (P  = .01 and P  = .003, respectively). CONCLUSION: The results of the present study have demonstrated that the HCT-CI and mEBMT are both prognostic for @entity1349 and NRM in our cohort. However, the mEBMT score can identify a favorable-risk subgroup of @entity1 not identifiable using the HCT-CI.
